JP2019530739A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530739A5
JP2019530739A5 JP2019532215A JP2019532215A JP2019530739A5 JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5 JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5
Authority
JP
Japan
Prior art keywords
pyridin
trifluoromethyl
sulfonamide
chloro
sulfamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530739A (ja
JP7035055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055162 external-priority patent/WO2018042316A1/en
Publication of JP2019530739A publication Critical patent/JP2019530739A/ja
Publication of JP2019530739A5 publication Critical patent/JP2019530739A5/ja
Application granted granted Critical
Publication of JP7035055B2 publication Critical patent/JP7035055B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532215A 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用 Expired - Fee Related JP7035055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380659P 2016-08-29 2016-08-29
US62/380,659 2016-08-29
PCT/IB2017/055162 WO2018042316A1 (en) 2016-08-29 2017-08-28 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Publications (3)

Publication Number Publication Date
JP2019530739A JP2019530739A (ja) 2019-10-24
JP2019530739A5 true JP2019530739A5 (enExample) 2020-08-27
JP7035055B2 JP7035055B2 (ja) 2022-03-14

Family

ID=59923496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532215A Expired - Fee Related JP7035055B2 (ja) 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用

Country Status (15)

Country Link
US (2) US10450273B2 (enExample)
EP (1) EP3504194B1 (enExample)
JP (1) JP7035055B2 (enExample)
KR (1) KR20190040319A (enExample)
CN (1) CN109641873B (enExample)
AR (1) AR109437A1 (enExample)
AU (1) AU2017319430A1 (enExample)
BR (1) BR112019003883A2 (enExample)
CA (1) CA3031073A1 (enExample)
EA (1) EA201990609A1 (enExample)
ES (1) ES2898069T3 (enExample)
MX (1) MX2019002439A (enExample)
TW (1) TW201811766A (enExample)
UY (1) UY37379A (enExample)
WO (1) WO2018042316A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR102825974B1 (ko) 2016-09-13 2025-06-30 삼성디스플레이 주식회사 표시 장치
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
JP2022514253A (ja) * 2018-12-18 2022-02-10 ノバルティス アーゲー N-(ピリジン-2-イルスルホニル)シクロプロパンカルボキサミド誘導体及びcftr媒介疾患の処置におけるその使用
EP3898621A1 (en) * 2018-12-21 2021-10-27 Novartis AG Macrocyclic compounds and their use in the treatment of disease
JP2022519301A (ja) * 2019-02-06 2022-03-22 ノバルティス アーゲー N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体及び疾患の処置におけるそれらの使用
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI867024B (zh) * 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
PE20221461A1 (es) * 2019-11-12 2022-09-21 Genzyme Corp Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
CA3157798A1 (en) * 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
US20230050418A1 (en) * 2019-12-13 2023-02-16 Rhodia Operations Production of benzene derivatives
CA3188787A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
BR112023002651A2 (pt) 2020-08-20 2023-04-04 Univ Leland Stanford Junior Métodos de tratamento de doenças respiratórias definidas por hipersecreção de muco
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5939431A (en) * 1996-06-20 1999-08-17 Schering Corporation Naphthyridines which affect IL-4 and G-CSF
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005040135A1 (ja) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005103022A1 (en) 2004-04-20 2005-11-03 Transtech Pharma, Inc. Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2576993C (en) 2004-08-12 2013-09-24 Amgen Inc. Bisaryl-sulfonamides
CA2582276C (en) 2004-10-04 2011-09-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP1922068A4 (en) 2005-08-16 2010-08-11 Icagen Inc INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
AU2006283944A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2049515B1 (en) 2006-07-14 2011-01-26 ChemoCentryx, Inc. Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
DK2420494T3 (en) 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
AU2007293653B2 (en) 2006-09-08 2011-02-17 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
US8084454B2 (en) 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CA2714232A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
EP2421368A4 (en) * 2009-04-20 2013-01-09 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS FOR PYRIDAZINE SULFONAMIDE DERIVATIVES
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
PH12012502551A1 (en) 2010-06-28 2017-08-23 Bayer Ip Gmbh Heterocyclic compounds as agents for pest control
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
CA2822789A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
US9056867B2 (en) * 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014028968A1 (en) 2012-08-21 2014-02-27 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2015097122A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Benzene sulfonamides as ccr9 inhibitors
EP3116870A1 (en) * 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN104844566B (zh) 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
CN107922338A (zh) * 2015-06-02 2018-04-17 艾伯维公司 经取代的吡啶及使用方法
US9981945B2 (en) 2015-10-07 2018-05-29 NuBridge BioSciences Pyrimidine derivatives as CFTR modulators
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途

Similar Documents

Publication Publication Date Title
JP2019530739A5 (enExample)
US11129832B2 (en) Biheteroaryl compounds and uses thereof
RU2484091C2 (ru) Производные изоксазоло-пиридина
AU2018204431B2 (en) Compounds useful as inhibitors of ATR kinase
JP5788415B2 (ja) Cdk4/6阻害剤としてのピロロピリミジン化合物
JP2017524007A5 (enExample)
CA2900855C (en) Aminopyrimidinyl compounds
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
ES2637588T3 (es) Nuevos compuestos tricíclicos
US20230233692A1 (en) Compounds for targeted degradation of ret
NL2000323C2 (nl) Pyrimidine-derivaten.
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JP2021506858A5 (enExample)
JP2019535664A5 (enExample)
JP2017505327A5 (enExample)
JP2018500376A5 (enExample)
JP2013515070A5 (enExample)
GB2609879A (en) Antagonists of the adenosine A2a receptor
EP2548877A1 (en) 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
HRP20210285T1 (hr) Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka
JP2015512427A5 (enExample)
JPWO2022208269A5 (enExample)
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
JPWO2021097009A5 (enExample)
RU2023134860A (ru) Ингибиторы мутации her2